Business Description
Pharming Group
ISIN : US71716E1055
Share Class Description:
PHAR: ADRTotal Employee Number:
409Compare
Compare
Traded in other countries / regions
PHARM.Netherlands0QCO.UKPHGUF.USAPHGN.Germany IPO Date
2020-12-23Description
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.46 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.43 | |||||
Debt-to-EBITDA | 2.69 | |||||
Interest Coverage | 1.78 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.2 | |||||
Beneish M-Score | -2.81 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.2 | |||||
3-Year EBITDA Growth Rate | -3.9 | |||||
3-Year EPS without NRI Growth Rate | 7.7 | |||||
3-Year FCF Growth Rate | 31.9 | |||||
3-Year Book Growth Rate | 4.7 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 75.41 | |||||
9-Day RSI | 61.4 | |||||
14-Day RSI | 53.06 | |||||
3-1 Month Momentum % | -16.49 | |||||
6-1 Month Momentum % | -23.48 | |||||
12-1 Month Momentum % | 25.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.63 | |||||
Quick Ratio | 2.06 | |||||
Cash Ratio | 1.51 | |||||
Days Inventory | 541.37 | |||||
Days Sales Outstanding | 49.44 | |||||
Days Payable | 573.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.3 | |||||
Shareholder Yield % | 0.7 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 88.16 | |||||
Operating Margin % | 5.79 | |||||
Net Margin % | 3.32 | |||||
EBITDA Margin % | 11.78 | |||||
FCF Margin % | 15.08 | |||||
OCF Margin % | 15.27 | |||||
ROE % | 4.78 | |||||
ROA % | 2.61 | |||||
ROIC % | 5.7 | |||||
3-Year ROIIC % | -17.28 | |||||
ROC (Joel Greenblatt) % | 59.65 | |||||
ROCE % | 8.56 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 72.44 | |||||
Forward PE Ratio | 22.4 | |||||
PE Ratio without NRI | 72.44 | |||||
Price-to-Owner-Earnings | 32.55 | |||||
PS Ratio | 2.7 | |||||
PB Ratio | 3.45 | |||||
Price-to-Tangible-Book | 6.72 | |||||
Price-to-Free-Cash-Flow | 17.54 | |||||
Price-to-Operating-Cash-Flow | 17.54 | |||||
EV-to-EBIT | 26.95 | |||||
EV-to-Forward-EBIT | 15.88 | |||||
EV-to-EBITDA | 19.7 | |||||
EV-to-Forward-EBITDA | 12.87 | |||||
EV-to-Revenue | 2.33 | |||||
EV-to-Forward-Revenue | 2.17 | |||||
EV-to-FCF | 15.44 | |||||
Price-to-GF-Value | 0.9 | |||||
Price-to-Projected-FCF | 1.96 | |||||
Price-to-Median-PS-Value | 0.67 | |||||
Price-to-Graham-Number | 4.74 | |||||
| Price-to-Net-Current-Asset-Value | 12.66 | |||||
Earnings Yield (Greenblatt) % | 3.71 | |||||
FCF Yield % | 6.09 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PHAR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pharming Group Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 369.455 | ||
| EPS (TTM) ($) | 0.18 | ||
| Beta | -0.5075 | ||
| 3-Year Sharpe Ratio | 0.18 | ||
| 3-Year Sortino Ratio | 0.33 | ||
| Volatility % | 61.12 | ||
| 14-Day RSI | 53.06 | ||
| 14-Day ATR ($) | 0.528493 | ||
| 20-Day SMA ($) | 12.749745 | ||
| 12-1 Month Momentum % | 25.88 | ||
| 52-Week Range ($) | 9.5354 - 21.34 | ||
| Shares Outstanding (Mil) | 70.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pharming Group Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pharming Group Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 07:00 | In 131 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 | In 130 days | ||
| Second quarter earnings results for 2026 | 2026-07-30 07:00 | In 32 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 | In 31 days | ||
| General meeting for 2026 | 2026-05-28 14:00 | 13.41 (-0.15%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 07:30 | 16.40 (-0.67%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 16.40 (-0.67%) | ||
| Annual report for 2025 | 2026-04-02 | 16.92 (-1.23%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-12 08:30 | 15.88 (-1.37%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 07:00 | 15.88 (-1.37%) |
Show
Entries
Pharming Group Frequently Asked Questions
What is Pharming Group(PHAR)'s stock price today?
The current price of PHAR is $13.04. The 52 week high of PHAR is $21.34 and 52 week low is $9.54.
When is next earnings date of Pharming Group(PHAR)?
The next earnings date of Pharming Group(PHAR) is 2026-07-30.
Does Pharming Group(PHAR) pay dividends? If so, how much?
Pharming Group(PHAR) does not pay dividend.
Guru Commentaries on NAS:PHAR
No articles.
Press Release
Articles on Pharming Group
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers